Partnership between Serum Institute of India and Gates MRI – A significant initiative towards the global production of the M72/AS01E vaccine against Tuberculosis (TB)
Serum Institute of India (SII) and Gates Medical Research Institute (Gates MRI) have entered into a collaboration agreement for the manufacturing and global supply of the M72/AS01E tuberculosis (TB) vaccine, which will be produced on a large scale following Phase III trials and regulatory approvals. M72/AS01E is an advanced vaccine candidate developed to prevent pulmonary TB in adults and adolescents; if successful, it would be the first new TB vaccine developed for adults in nearly 100 years. As the world's largest vaccine manufacturer, SII supplies vaccines to over 170 countries, and this partnership will further strengthen India's global identity as the 'Pharmacy of the World.' This initiative supports the WHO's 'End TB Strategy' and SDG-3 goals while reinforcing India's capabilities in global vaccine research and public health leadership.
Serum Institute of India (SII) and Gates Medical Research Institute (Gates MRI) have signed a significant collaboration agreement for the manufacturing and global supply of the M72/AS01E tuberculosis (TB) vaccine. Subject to the success of Phase III clinical trials and the receipt of regulatory approvals, SII will undertake large-scale production of the vaccine. This initiative marks a crucial step towards strengthening TB control, particularly in low- and middle-income countries.
What is the M72/AS01E vaccine?
M72/AS01E is an advanced vaccine candidate developed to prevent pulmonary tuberculosis in adults and adolescents. It was initially developed by GlaxoSmithKline (GSK), and Gates MRI is currently leading its development and testing. If successful, it will be the first new TB vaccine developed for adults in nearly a century and will serve as a crucial complement to the existing BCG (Bacillus Calmette–Guérin) vaccine, which primarily protects infants against severe forms of TB.
Role of the Serum Institute of India (SII)
The Serum Institute of India (SII), based in Pune, is the world's largest vaccine manufacturer by volume. It supplies vaccines to over 170 countries and plays a leading role in producing vaccines for various infectious diseases, including polio, measles, meningitis, influenza, and COVID-19. This new partnership further strengthens India's global vaccine manufacturing capabilities and its identity as the 'Pharmacy of the World.'
Significance for Global Health
Tuberculosis remains one of the world's deadliest infectious diseases. According to the World Health Organization (WHO), India is among the countries with the highest burden of TB. The success of the M72/AS01E vaccine would significantly aid in TB control, mortality reduction, and the achievement of the WHO's 'End TB Strategy' and the Sustainable Development Goals (SDG-3: Good Health and Well-being).
SII's Other Global Research Initiatives
SII is also actively involved in developing next-generation vaccines against infectious diseases. The institute has initiated Phase-I clinical trials for the Bundibugyo Ebola vaccine in collaboration with the Jenner Institute and the Oxford Vaccine Group at the University of Oxford. Additionally, multinational clinical trials for a dengue vaccine are being conducted in Brazil, Malaysia, and Thailand, further reinforcing India's role in global vaccine research.
Significance for the UPSC Examination
This topic is highly relevant for GS Paper-3 (Science and Technology, Biotechnology, and Health) and GS Paper-2 (Health Policy and Social Sector). Facts related to the BCG vaccine, M72/AS01E, the WHO End TB Strategy, the National TB Elimination Programme (NTEP), Gates MRI, the Serum Institute of India, and Phase I, II, and III clinical trials may be asked in the preliminary examination, whereas analytical questions regarding TB elimination, vaccine research, public health infrastructure, and India's vaccine diplomacy could be asked in the main examination.
